Payment overview · 2025
General Payments
$817.16
36 reported records · 14 companies
Healthcare provider profile · identity verified
William Tsai, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · UPLAND, CA · NPI 1285620443
Verified facts
What the public records show
CMS Open Payments records show William Tsai, D.O. received $817.16 in general payments during 2025 across 36 reported records.
Novo Nordisk Inc accounted for 19.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Lokelma by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $157.80 | 19.3% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $111.69 | 13.7% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $88.71 | 10.9% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $82.28 | 10.1% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $69.31 | 8.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.54 | 7.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.66 | 6.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $40.03 | 4.9% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $36.66 | 4.5% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $27.87 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.23 | 3.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.69 | 3.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.07 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.62 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $817.16 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $88.71 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $82.28 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $82.28 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $81.96 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $75.84 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $69.31 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.41 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $63.54 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $55.66 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $46.28 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $40.03 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $40.03 | 2 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $40.03 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $36.66 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $28.22 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $27.87 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.23 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.23 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.23 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| VAQTA Normalized: vaqta |
Biological | Merck Sharp & Dohme LLC | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 77 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 158 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
47 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
158 | 36 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 805 | 203 |
| Amlodipine Besylate | Amlodipine Besylate | 533 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 391 | 78 |
| Losartan Potassium | Losartan Potassium | 367 | 100 |
| Metformin Hcl | Metformin Hcl | 288 | 82 |
| Trazodone Hcl | Trazodone Hcl | 234 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 225 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 219 | 56 |
| Carvedilol | Carvedilol | 194 | 50 |
| Jardiance | Empagliflozin | 158 | 36 |
| Furosemide | Furosemide | 155 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 152 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 132 | 31 |
| Omeprazole | Omeprazole | 126 | 32 |
| Memantine Hcl | Memantine Hcl | 124 | 18 |
| Benazepril Hcl | Benazepril Hcl | 117 | 25 |
| Alendronate Sodium | Alendronate Sodium | 112 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 31 |
| Cephalexin | Cephalexin | 105 | 58 |
| Finasteride | Finasteride | 104 | 25 |
| Gabapentin | Gabapentin | 104 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 30 |
| Famotidine | Famotidine | 99 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 26 |
| Ozempic | Semaglutide | 91 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 27 |
| Lorazepam | Lorazepam | 89 | 20 |
| Baclofen | Baclofen | 85 | 18 |
| Levetiracetam | Levetiracetam | 85 | 13 |
| Donepezil Hcl | Donepezil Hcl | 83 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 12 |
| Potassium Chloride | Potassium Chloride | 79 | 23 |
| Tramadol Hcl | Tramadol Hcl | 79 | 15 |
| Farxiga | Dapagliflozin Propanediol | 77 | 23 |
| Lactulose | Lactulose | 76 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 20 |
| Lisinopril | Lisinopril | 74 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 16 |
| Divalproex Sodium | Divalproex Sodium | 71 | suppressed |
| Mirtazapine | Mirtazapine | 71 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | suppressed |
| Ezetimibe | Ezetimibe | 70 | 19 |
| Montelukast Sodium | Montelukast Sodium | 68 | 15 |
| Eliquis | Apixaban | 66 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 20 |
| Prednisone | Prednisone | 63 | 15 |
| Azithromycin | Azithromycin | 61 | 39 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 19 |
| Myrbetriq | Mirabegron | 55 | 12 |
| Alprazolam | Alprazolam | 53 | suppressed |
| Ibuprofen | Ibuprofen | 50 | 16 |
| Clonidine Hcl | Clonidine Hcl | 48 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 13 |
| Prolia | Denosumab | 47 | 29 |
| Glipizide | Glipizide | 44 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Amoxicillin | Amoxicillin | 35 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 11 |
| Labetalol Hcl | Labetalol Hcl | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Lidocaine | Lidocaine | 32 | suppressed |
| Methimazole | Methimazole | 31 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Constulose | Lactulose | 29 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Nystatin | Nystatin | 26 | 12 |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Scopolamine | Scopolamine | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Procto-Med Hc | Hydrocortisone | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Humulin R | Insulin Regular, Human | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Permethrin | Permethrin | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nikki | Ethinyl Estradiol/Drospirenone | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Dapsone | Dapsone | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Rytary | Carbidopa/Levodopa | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $817.16 · 36 records | Novo Nordisk Inc | ABRYSVO, CAPVAXIVE, COMIRNATY, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ENTRESTO, FARXIGA, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, Kerendia, Korlym, LEQVIO, M-M-R II, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VAQTA, Wegovy, XIFAXAN | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error